Bryant E C, Hart G D, Cairns D, Gamarra J A, de Veber L L, Holland C G, Hutchison J L
Can Med Assoc J. 1969 Dec 13;101(12):82-3.
-During 1966, clinical trials were conducted in three Canadian centres to determine the safety and efficacy of Rh(0)(D) immune globulin (human) in preventing isoimmunization by the Rh(0)(D) antigen in Rh-negative women delivering ABO-compatible Rh-positive infants.The candidates were randomly divided into control and treated groups; the treated mothers received an intramuscular injection of 300 mug. of anti-Rh(0)(D) within 72 hours of delivery. Follow-up antibody screening tests were conducted on the sera of all patients six to nine months post partum.Of the 175 control patients, 11 or 6.2% became actively immunized to the Rh antigen, whereas complete protection against maternal Rh immunization was observed in the 191 treated patients.
1966年期间,在加拿大的三个中心进行了临床试验,以确定Rh(0)(D)免疫球蛋白(人)在预防分娩ABO血型相容的Rh阳性婴儿的Rh阴性妇女中因Rh(0)(D)抗原产生同种免疫方面的安全性和有效性。将受试者随机分为对照组和治疗组;治疗组的母亲在分娩后72小时内接受300微克抗Rh(0)(D)的肌肉注射。在产后六至九个月对所有患者的血清进行随访抗体筛查试验。175名对照患者中,11名(6.2%)对Rh抗原产生了主动免疫,而191名治疗患者中观察到对母体Rh免疫的完全保护。